 No interaction studies have been conducted.As with other monoclonal antibodies, the interaction potential is considered to be low.Mepolizumab binds to IL-5 and prevents it from binding to its receptor, more specifically the interleukin 5 receptor alpha subunit, on the surface of eosinophil white blood cells.